Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 42 · MACD above its signal
None of the 29 investors followed here reported a position in INTS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INTS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Talamo Joseph CpaChief Financial Officer | Stock Award(Grant) at price 3.48 per share. | 1.1K | $3.81K |
| Jun 29, 2026 | Wesolowski John M CpaOfficer | Stock Award(Grant) at price 3.48 per share. | 3.7K | $12.85K |
| Mar 25, 2026 | Bender Lewis HChief Executive Officer | Stock Award(Grant) at price 6.11 per share. | 37.7K | $230.65K |
| Dec 30, 2025 | Talamo Joseph CpaChief Financial Officer | Stock Award(Grant) at price 0.26 per share. | 14.5K | $3.79K |
| Dec 30, 2025 | Wesolowski John M CpaOfficer | Stock Award(Grant) at price 0.26 per share. | 8.9K | $2.34K |
| Jun 29, 2025 | Talamo Joseph CpaChief Financial Officer | Stock Award(Grant) at price 0.26 per share. | 14.2K | $3.70K |
| Jun 29, 2025 | Wesolowski John M CpaOfficer | Stock Award(Grant) at price 0.26 per share. | 69.7K | $18.20K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.7 | -16.3 | -23.2 | -11.4 | -15.7 | -6.6 | 1.2 | 1.4 | -20.0 | 1.5 | −66.6% | ||
| 2025 | 25.6 | 5.9 | -15.8 | -70.2 | -19.2 | -35.4 | -9.8 | 1.8 | -13.8 | 200.4 | -45.3 | 2.8 | −76.7% |
| 2024 | -42.6 | -24.8 | 40.5 | -25.0 | 27.4 | -1.4 | -1.2 | -10.1 | -12.2 | -14.9 | -10.0 | -39.8 | −79.5% |
| 2023 | -4.0 | 0.9 | -31.2 | -23.7 | -19.1 | 249.7 | +43.8% |
Buy / hold / sell counts
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.